PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 7272人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255081, encodeId=927512550812d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, objectType=article, longId=198551, objectId=2cb719855145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb719855145, replyNumber=0, likeNumber=69, createdTime=2020-08-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb719855145, moduleTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb719855145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255080, encodeId=089f1255080ac, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性, objectType=article, longId=198067, objectId=a92519806e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a92519806e26, replyNumber=0, likeNumber=67, createdTime=2020-07-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a92519806e26, moduleTitle=Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a92519806e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255079, encodeId=0de312550e91a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, objectType=article, longId=197602, objectId=cbf019e602e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf019e602e0, replyNumber=0, likeNumber=67, createdTime=2020-07-17, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf019e602e0, moduleTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf019e602e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255078, encodeId=49b012550e8b8, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, objectType=article, longId=197518, objectId=29ba19e518a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ba19e518a8, replyNumber=0, likeNumber=74, createdTime=2020-07-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ba19e518a8, moduleTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ba19e518a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255077, encodeId=489b12550e735, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Brit J Cancer：抗PD-L1免疫治疗和放疗联用对肿瘤免疫微环境的影响 , objectType=article, longId=197412, objectId=512719e41250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=512719e41250, replyNumber=0, likeNumber=86, createdTime=2020-07-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=512719e41250, moduleTitle=Brit J Cancer：抗PD-L1免疫治疗和放疗联用对肿瘤免疫微环境的影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=512719e41250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255076, encodeId=a75812550e6e5, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, objectType=article, longId=196892, objectId=c2de19689221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2de19689221, replyNumber=0, likeNumber=77, createdTime=2020-07-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2de19689221, moduleTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2de19689221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255075, encodeId=b9fa12550e5aa, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=郑利民教授分享肝癌组织PD-L1的表达、调控与临床意义, objectType=article, longId=196707, objectId=9c46196e07c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c46196e07c6, replyNumber=0, likeNumber=67, createdTime=2020-06-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c46196e07c6, moduleTitle=郑利民教授分享肝癌组织PD-L1的表达、调控与临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c46196e07c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255074, encodeId=d46a12550e4c2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, objectType=article, longId=196545, objectId=5a8619654517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a8619654517, replyNumber=0, likeNumber=77, createdTime=2020-06-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a8619654517, moduleTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a8619654517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255073, encodeId=62a012550e3b6, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, objectType=article, longId=196482, objectId=3e9419648230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e9419648230, replyNumber=0, likeNumber=54, createdTime=2020-06-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e9419648230, moduleTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e9419648230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255072, encodeId=62e512550e20f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, objectType=article, longId=196293, objectId=15011962937c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15011962937c, replyNumber=0, likeNumber=71, createdTime=2020-06-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15011962937c, moduleTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15011962937c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255071, encodeId=e72812550e12c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=针对抗PD-1/PD-L1治疗后进展的黑色素瘤：G蛋白雌激素受体激动剂LNS8801获得FDA快速通道, objectType=article, longId=196199, objectId=04db19619962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04db19619962, replyNumber=0, likeNumber=85, createdTime=2020-06-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04db19619962, moduleTitle=针对抗PD-1/PD-L1治疗后进展的黑色素瘤：G蛋白雌激素受体激动剂LNS8801获得FDA快速通道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04db19619962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255070, encodeId=168d12550e0ed, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, objectType=article, longId=196192, objectId=ea03196192c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea03196192c4, replyNumber=0, likeNumber=102, createdTime=2020-06-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea03196192c4, moduleTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea03196192c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255069, encodeId=d6b212550691f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO 2020 | 后起之秀：靶向PD-L1的前体治疗药物CX-072, objectType=article, longId=195529, objectId=cb091955294a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb091955294a, replyNumber=0, likeNumber=77, createdTime=2020-06-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb091955294a, moduleTitle=ASCO 2020 | 后起之秀：靶向PD-L1的前体治疗药物CX-072, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb091955294a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255068, encodeId=57ce12550683f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, objectType=article, longId=195499, objectId=9c0719549995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0719549995, replyNumber=0, likeNumber=98, createdTime=2020-06-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0719549995, moduleTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0719549995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255067, encodeId=7fff125506e94, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO 2020：低免疫毒副作用的PD-L1抗体令人叹服, objectType=article, longId=195027, objectId=24f119502e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24f119502e0a, replyNumber=0, likeNumber=64, createdTime=2020-06-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24f119502e0a, moduleTitle=ASCO 2020：低免疫毒副作用的PD-L1抗体令人叹服, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24f119502e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255066, encodeId=d909125506605, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, objectType=article, longId=194614, objectId=d3b0194614fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b0194614fc, replyNumber=0, likeNumber=135, createdTime=2020-05-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b0194614fc, moduleTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3b0194614fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255065, encodeId=c2381255065b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗, objectType=article, longId=194430, objectId=b3b9194430bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b9194430bd, replyNumber=0, likeNumber=84, createdTime=2020-05-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b9194430bd, moduleTitle=美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b9194430bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255064, encodeId=11791255064f7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, objectType=article, longId=194315, objectId=4a69194315ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a69194315ed, replyNumber=0, likeNumber=82, createdTime=2020-05-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a69194315ed, moduleTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a69194315ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255063, encodeId=7bf8125506371, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Chest：非小细胞肺癌支气管超声引导下经支气管针吸活检术检测PD-L1, objectType=article, longId=194290, objectId=03ae194290d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03ae194290d0, replyNumber=0, likeNumber=32, createdTime=2020-05-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03ae194290d0, moduleTitle=Chest：非小细胞肺癌支气管超声引导下经支气管针吸活检术检测PD-L1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03ae194290d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255062, encodeId=41291255062f3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Med：IL-8与PD-L1抑制剂在泌尿系肿瘤的临床获益减少有关, objectType=article, longId=194253, objectId=349a19425314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=349a19425314, replyNumber=0, likeNumber=83, createdTime=2020-05-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=349a19425314, moduleTitle=Nat Med：IL-8与PD-L1抑制剂在泌尿系肿瘤的临床获益减少有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=349a19425314)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法

2020-08-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性

2020-07-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌

2020-07-17

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败

2020-07-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Brit J Cancer：抗PD-L1免疫治疗和放疗联用对肿瘤免疫微环境的影响

2020-07-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗

2020-07-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

郑利民教授分享肝癌组织PD-L1的表达、调控与临床意义

2020-06-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率

2020-06-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗

2020-06-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌

2020-06-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

针对抗PD-1/PD-L1治疗后进展的黑色素瘤：G蛋白雌激素受体激动剂LNS8801获得FDA快速通道

2020-06-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功

2020-06-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ASCO 2020 | 后起之秀：靶向PD-L1的前体治疗药物CX-072

2020-06-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌

2020-06-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ASCO 2020：低免疫毒副作用的PD-L1抗体令人叹服

2020-06-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌

2020-05-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗

2020-05-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期

2020-05-19

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Chest：非小细胞肺癌支气管超声引导下经支气管针吸活检术检测PD-L1

2020-05-19

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Med：IL-8与PD-L1抑制剂在泌尿系肿瘤的临床获益减少有关

2020-05-18

科室
- - 订阅+
  - 更多科室
工具
服务